Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndromeCentral MessagePerspective

Objective: To assess the safety and feasibility of low-dose, novel, allogenic mesenchymal precursor cell (MPC) therapy as an adjunct to left ventricular (LV) recruitment for patients with hypoplastic left heart syndrome (HLHS) and borderline left ventricles. MPC injections into the hypoplastic left...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Rachel E. Wittenberg, BS, Kimberlee Gauvreau, ScD, Jonah Leighton, CST, Melinda Moleon-Shea, BS, Kenneth M. Borow, MD, Gerald R. Marx, MD, Sitaram M. Emani, MD
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2023-12-01
Serie:	JTCVS Open
Ämnen:	hypoplastic left heart syndrome biventricular conversion left ventricular recruitment stem cell therapy congenital heart disease regenerative medicine
Länkar:	http://www.sciencedirect.com/science/article/pii/S2666273623003042
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!